

Australian Government

Department of Health and Aged Care Therapeutic Goods Administration

Ingredient Summary

Ingredient Name	Curcuma longa		
Ingredient ID	65400		
Category	Approved Herbal Name		
Synonyms	Turmeric		
CAS Number	CAS Number not held on file		
Availability	Available for use as an Active Ingredient in: Export Only, Listed Medicines, Over the Counter, Prescription Medicines		
	Also available for use as a Homoeopathic Ingredient in Listed Medicines		
	Available for use as an Excipient Ingredient in: Devices, Export Only, Listed Medicines, Over the Counter, Prescription Medicines		
	Not available as an Equivalent Ingredient in any application		
	Please note: Only the name and definition of a substance have been reviewed to allow it to be included in the ingredient repository. The approval for use of the ingredient in therapeutic goods is a decision made by the relevant TGA regulatory area. This approval process may require submission of further information, for example safety data for the ingredient or for the finished goods, to meet legislative and regulatory requirements.		
Additional Informatio	n		

Naming Reference

Reference	Edition/Year/Volume	Page Number(s)	Accessed Online
Medicinal Plant Names Services			Yes - 18 Apr 2018

Restrictions

Restriction	Applies To
The requirements specified in paragraphs (a) to (c) below apply to a medicine	Listed Medicines
that contains the ingredient that is:	
- listed in the Register on or after 1 March 2024; or	
- released for supply on or after 1 March 2025.	
(a) When used in oral medicines as an active ingredient, the following warning	
statement is required on the medicine label:	
'In very rare cases, Curcuma species may harm the liver. Stop use and see a	
doctor if you have yellowing skin/eyes or unusual: fatigue, nausea, appetite	
loss, abdominal pain, dark urine, or itching.'	
(b) When used in oral medicines the maximum daily dose of	
(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione in the	
medicine must not provide more than:	
(i) 36 mg for children from 2-3 years (inclusive);	
(ii) 48 mg for children from 4-11 years (inclusive); and	
(iii) 123 mg for children from 12-17 years (inclusive).	
(c) Not permitted for use in children aged below 2 years.	

PO Box 100 Woden ACT 2606 - ABN 40 939 406 804

Phone: 1800 020 653 Fax: 02 6203 1605 Email: info@tga.gov.au www.ebs.tga.gov.au

END OF SUMMARY

Disclaimer: The details contained in this document reflect the information held at the nominated date and time of printing. The most recent version of this document can be accessed at www.ebs.tga.gov.au. Please refer to TGA's disclaimer by clicking on the following link Disclaimer.

© Commonwealth of Australia 2016.

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to tga.copyright@tga.gov.au.